Nuvalent, Inc. (NUVL)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
123.94 USD
+0.04
(0.032%)
⇧
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 2:58 a.m. EDT
Nuvalent is trading at the precipice of a GSK acquisition, priced just shy of the reported $124 cash offer. While the stock has rallied nearly fourfold over the last three years, the underlying financials tell a different story: negative earnings, negative free cash flow, and a return on equity of negative forty-one percent. The recent price surge is clearly driven by the buyout rumor rather than operational improvement. Options flow shows aggressive call buying targeting prices above the buyout threshold, but the elevated put implied volatility suggests investors are wary of deal failure. For a long-term investor, the negative fundamentals and high risk profile warrant caution; the current valuation is entirely dependent on the transaction completion. Short-term traders may find momentum here, but the lack of organic growth makes this a speculative play on M&A rather than a fundamental investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.067369 |
| AutoETS | 0.068140 |
| AutoARIMA | 0.068232 |
| MSTL | 0.069514 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 22.80 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.691 |
| Excess Kurtosis | -0.42 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 9,791,001,600 |
| Forward P/E | -30.00 |
| Beta | 1.14 |
| Website | https://nuvalent.com |
As of July 11, 2026, 2:58 a.m. EDT: Call volume is heavily skewed toward out-of-the-money strikes, with ninety-six percent of open interest in OTM positions for the nearest expiration, indicating bullish speculation on a price move above current levels. Notable new flow appears at the 120 and 130 strikes. However, implied volatility for puts is significantly higher than calls in the near term, suggesting investors are hedging against downside risk or anticipating deal uncertainty.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.46471214 |
| Address1 | One Broadway |
| Address2 | 14th Floor |
| All Time High | 123.91 |
| All Time Low | 7.09 |
| Ask | 123.96 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 1,660,580 |
| Average Daily Volume3 Month | 2,264,562 |
| Average Volume | 2,264,562 |
| Average Volume10Days | 1,660,580 |
| Beta | 1.138 |
| Bid | 123.94 |
| Bid Size | 5 |
| Board Risk | 4 |
| Book Value | 14.888 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 123.94 |
| Current Ratio | 16.137 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 123.97 |
| Day Low | 123.87 |
| Display Name | Nuvalent |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 8,503,525,376 |
| Eps Current Year | -5.47538 |
| Eps Forward | -4.13175 |
| Eps Trailing Twelve Months | -6.06 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 110.7544 |
| Fifty Day Average Change | 13.1856 |
| Fifty Day Average Change Percent | 0.119052604 |
| Fifty Two Week Change Percent | 46.471214 |
| Fifty Two Week High | 123.97 |
| Fifty Two Week High Change | -0.02999878 |
| Fifty Two Week High Change Percent | -0.00024198418 |
| Fifty Two Week Low | 71.13 |
| Fifty Two Week Low Change | 52.810005 |
| Fifty Two Week Low Change Percent | 0.7424435 |
| Fifty Two Week Range | 71.13 - 123.97 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,565,400,000 |
| Float Shares | 49,108,264 |
| Forward Eps | -4.13175 |
| Forward P E | -29.996975 |
| Free Cashflow | -180,427,744 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 234 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02781 |
| Held Percent Institutions | 1.1327 |
| Implied Shares Outstanding | 78,997,915 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-29 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Nuvalent, Inc. |
| Market | us_market |
| Market Cap | 9,791,001,600 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_702442629 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -450,073,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 9,807,154,188 |
| Number Of Analyst Opinions | 16 |
| Open | 123.88 |
| Operating Cashflow | -312,787,008 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 857 357 7000 |
| Previous Close | 123.9 |
| Price Eps Current Year | -22.635872 |
| Price Hint | 2 |
| Price To Book | 8.324826 |
| Profit Margins | 0.0 |
| Quick Ratio | 15.885 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0400009 |
| Regular Market Change Percent | 0.0322848 |
| Regular Market Day High | 123.97 |
| Regular Market Day Low | 123.87 |
| Regular Market Day Range | 123.87 - 123.97 |
| Regular Market Open | 123.88 |
| Regular Market Previous Close | 123.9 |
| Regular Market Price | 123.94 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 2,456,744 |
| Return On Assets | -0.22513 |
| Return On Equity | -0.41189 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 73,562,661 |
| Shares Percent Shares Out | 0.0368 |
| Shares Short | 2,908,403 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 5,241,004 |
| Short Name | Nuvalent, Inc. |
| Short Percent Of Float | 0.0617 |
| Short Ratio | 0.56 |
| Source Interval | 15 |
| State | MA |
| Symbol | NUVL |
| Target High Price | 140.0 |
| Target Low Price | 124.0 |
| Target Mean Price | 125.125 |
| Target Median Price | 124.0 |
| Total Cash | 1,287,475,968 |
| Total Cash Per Share | 16.298 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -6.06 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 102.76408 |
| Two Hundred Day Average Change | 21.175926 |
| Two Hundred Day Average Change Percent | 0.20606351 |
| Type Disp | Equity |
| Volume | 2,456,744 |
| Website | https://nuvalent.com |
| Zip | 2,142 |